Investors and Media
     
     
  Events, Presentations and Webcasts
 
Press Releases
 
  Bionovo in the News
 
  Publications
 
  FAQ
 
  Stock Details
 
  Analyst Coverage
 
  SEC Filings
 
  SEC Filings - XBRL Content
 
  Corporate Governance
 
 

BIONOVO, INC.

$N/A (N/A)

BNVI.PK

Press Release

Back

Printer Friendly Version View printer-friendly version

Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer

EMERYVILLE, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) announced today that its drug candidate for metastatic breast cancer, BZL101, will advance to Phase 2 clinical testing after the successful completion of a second Phase 1 clinical trial.

The Phase 1B clinical trial was conducted to identify the maximum tolerated dose of BZL101 and to determine the safety and feasibility of the company's novel, oral, anticancer treatment. A total of 27 women with metastatic breast cancer were enrolled to this Phase 1B trial. A total of 48 women with advanced breast cancer have been treated with BZL101 in all clinical trials to date. Results from the Phase 1B show Bionovo's lead drug candidate for advanced breast cancer continues to be safe and well-tolerated, with early signs of clinical efficacy. The company will present the findings from the Phase 1B in an oral presentation of the best scoring abstracts at the Society of Integrative Oncology's Fifth International Conference on November 20, 2008 in Atlanta, Georgia.

"We are encouraged by the results of the Company's second Phase 1 trial in women with advanced breast cancer," said Isaac Cohen, President and CEO, Bionovo. "There are currently over 160,000 women in the United States living with advanced breast cancer who are eagerly awaiting an oral anticancer drug with minimal side effects and the ability to extend life without profoundly diminishing quality of life. We believe BZL101 may be an important new anticancer agent because its biological selectivity allows the drug to kill cancer cells without affecting normal cells. This will lead to a dramatically lower side effect profile."

Phase 2 Clinical Trial

The Phase 2 clinical trial is currently enrolling 80 women diagnosed with advanced, measurable breast cancer who have received no more than two prior cytotoxic cancer therapies.

The Principle Investigator of the trial is Dr. Charles Shapiro, Director of Breast Oncology at Ohio State University.

The trial will be open at the following clinical sites under the directorship of the listed investigators:




    Institution                               Site Principle Investigator

    Breastlink Medical Group, Long Beach,

     California                               Dr. Bichlien Nguyen

    California Cancer Care Inc.,

     Greenbrae/San Mateo, California          Dr. Peter Eisenberg

    Columbia Presbyterian Medical Center,

     New York, New York                       Dr. Dawn Hershman

    Comprehensive Cancer Center at Desert

     Regional Medical Center, Palm Springs,

     California                               Dr. Gail Leichman

    Duke University, Durham, North Carolina   Dr. Gretchen Kimmick

    Lynn Regional Cancer Center, Boca Raton,

     Florida                                  Dr. Reshma Mahtani

    MD Anderson, Houston, Texas               Dr. Banu Arun

    Memorial Cancer Institute, Hollywood,

     Florida                                  Dr. Alejandra Perez

    Montefiore Medical Center, Bronx,

     New York                                 Dr. Tianhong Li

    Ohio State University, Columbus, Ohio     Dr. Ewa Mrozek

    St. Vincent's Medical Center, New York,

     New York                                 Dr. Paula Klein

    University of California, San Francisco   Dr. Hope Rugo



    University of Chicago, Chicago, Illinois  Dr. Gini Fleming

    University of Miami, Miami, Florida       Dr. Alberto Montero

    University of Pittsburg Magee Women's

     Hospital, Pittsburg, Pennsylvania        Dr. Adam Brufsky

    University of Southern California,

     Los Angeles, California                  Dr. Agustin Garcia

    University of Texas, Southwestern,

     Dallas, Texas                            Dr. Jenny Li





BZL101

BZL101 is an oral drug designed for the treatment of advanced breast cancer with a novel mechanism of action. BZL101 targets diseased cells while leaving normal cells healthy and intact. Normal cells depend primarily on the citric acid cycle (>85%) and very little on glycolysis (<7%) for energy production. Cancer cells depend largely on glycolysis (>85%) for energy production. BZL101 stops the production cycle of energy in cancer cells by inhibiting glycolysis. This leads to DNA damage and cell death in cancer cells while normal cells remain unharmed.

There are currently no effective therapeutic cures for advanced breast cancer and treatment is primarily aimed at palliation of symptoms as well as improving overall survival. Over 200,000 women in the United States are diagnosed with breast cancer each year and breast cancer is the second leading cause of cancer death in women. Although survival after breast cancer treatment is improving, there are still over 40,000 deaths per year due to the disease in the Unites States alone.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.


SOURCE  Bionovo, Inc.

    -0-                             11/03/2008

    /CONTACT:  Tom Chesterman of Bionovo, Inc., +1-510-601-2000,

investor@bionovo.com/

    /Web site:  http://www.bionovo.com /

    (BNVI)



CO:  Bionovo, Inc.

ST:  California

IN:  HEA MTC

SU:  TRI



AB-DW

-- AQM111A --

5639 11/03/2008 16:41 EST http://www.prnewswire.com